Eduardo Ruman (In Memoriam)
Diretor-Presidente
Administrativo e Empreendedor
Denise Ruman
MTB - 0086489
JORNALISTA RESPONSÁVEL
The Biggest and Best International Newspaper for World Peace
Founder, President And International General Chief-Director  :  Denise Ruman - MTB: 0086489 / SP-BRAZIL
Mentor do Jornal / Mentor of the Newspaper  :  José Cardoso Salvador (in memoriam)
Mentor-Director / Mentor-Director  :  Mahavátar Babají (in memoriam)

Saúde / 10/06/2021

COVID 19 NEWS

Janssen vaccine that arrives in Brazil is effective against variants: single dose

0 votes
Janssen vaccine that arrives in Brazil is effective against variants: single dose

Fonte TheHill/Nature

Janssen vaccine, the Johnson & Johnson group, which is being awaited in Brazil, produces several immune responses that allow it to be effective against different variants of the virus, according to a study released on Wednesday, 9.

The research, published in Nature as an accelerated sample of an article, determined that the Johnson & Johnson vaccine activated immune responses against the original COVID-19 strain, as well as the Alpha, Beta, Gamma and Epsilon variants.

The study concluded that the Johnson & Johnson vaccine “offered strong protection against symptomatic cases” of COVID-19 in South Africa and Brazil, the variants caused the majority of sequenced cases.

Research

The researchers studied the cellular and antibody immune responses of 20 volunteers between the ages of 18 and 55 years.

The study found that fewer neutralizing antibodies appeared in the fight against the Beta and Gamma variants, first found in South Africa and Brazil, respectively, when compared to the original COVID-19 strain.

The study determined that a single dose of Johnson & Johnson vaccine protected against severe COVID-19 in 86 percent of participants in the United States, 88 percent of those in Brazil, and 82 percent in South Africa.

Since the Food and Drug Administration issued an emergency use authorization for the Johnson & Johnson vaccine in February, more than 11.2 million doses of the vaccine have been administered in the US.

arrival in Brazil

Brazil awaits the arrival of 3 million doses even now in June. The immunizing agent was approved by Anvisa in Brazil on March 31st.

In addition, the Ministry of Health signed an agreement with Janssen for the acquisition of 38 million doses of the company's vaccine, with an initial forecast to deliver 16.9 million doses between July and September and 21.1 million October to December.

Janssen's immunizing agent, which is currently used in the countries of the European Union, the United States and South Africa, received, in Brazil, a certificate of good practices Anvisa.

According to the US Centers for Disease Control and Prevention (CDC), the risk of allergic reactions to Janssen's vaccine is considered extremely low, especially when it comes to anaphylactic shock.

The immunizing agent has no compounds that can cause strong allergic reactions, such as antibiotics, adjuvants or preservatives, additives used to boost the immune response, according to the CDC. They can also be in other immunobiologicals.

TheHill/Nature


Comentários
0 comentários


  • Enviar Comentário
    Para Enviar Comentários é Necessário estar Logado.
    Clique Aqui para Entrar ou Clique Aqui para se Cadastrar.

Ainda não Foram Enviados Comentários!
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO

Copyright 2021 - Jornal Pacifista - All rights reserved. powered by WEB4BUSINESS

Inglês Português Frances Italiano Alemão Espanhol Árabe Bengali Urdu Esperanto Croata Chinês Coreano Grego Hebraico Japonês Hungaro Latim Persa Polonês Romeno Vietnamita Swedish Thai Czech Hindi Você